SLRN - רווח נקי למניה (EPS TTM) Acelyrin Inc.

Analyzing the chart in GURU.Markets, we note volatility in the rolling annual earnings per share for Acelyrin, Inc. (SLRN), where the figure stands at -2.70. This price action reflects the development of selective therapies for skin and joints. Growth is driven by isobelibag trials and potential licensing agreements, while operations remain strictly limited by FDA medical regulations regarding the disposal of biomaterials.

Net income per share over 12 months measures the portion of total income attributable to a single security. This metric is calculated by dividing the total trailing twelve-month profit by the current number of shares outstanding. Analyzing this chart of net income per share over the last 12 months allows for an assessment of capitalization efficiency. For Acelyrin, Inc. (SLRN), this price action confirms business resilience within an autonomous product cycle. Innovative developments make the company a reliable defensive asset, independent of global macroeconomic fluctuations.